> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Arthritis Drug Panel to Review Janssen BLA
- URL: https://www.fdaweb.com/arthritis-drug-panel-to-review-janssen-bla/
- Published: 2017-06-26T12:00:00.000Z
- Updated: 2026-09-14T22:31:25.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5139020

*Federal Register* notice: FDA has announced an 8/2 Arthritis Advisory Committee meeting to discuss a Janssen Biotech BLA for Plivensia (sirukumab injection). The submission is seeking approval for treating adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or are intolerant to one or more disease modifying anti-rheumatic drugs. The discussion will include dose selection, efficacy, radiographic progression study, and safety. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-06-26/pdf/2017-13203.pdf?ref=fdaweb.com).